Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1652
-0.0031(-0.26%)
GBP/USD
1.2546
+0.0013(+0.11%)
Bitcoin GBP
50,905.03
+3,658.37(+7.74%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Taysha Gene Therapies, Inc. (TSHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

2.5700

-0.0100

(-0.39%)

At close: 04:00PM EDT

2.6500

+0.08

(+3.11%)

After hours:

05:15PM EDT

Currency in USD

Valuation measures⁴

Market cap (intra-day)	480.64M
Enterprise value	397.80M
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	19.31
Price/book (mrq)	6.41
Enterprise value/revenue	25.75
Enterprise value/EBITDA	-3.78

Trading information

Stock price history

Beta (5Y monthly)	0.26
52-week change ³	263.38%
S&P500 52-week change ³	22.38%
52-week high ³	3.8900
52-week low ³	0.5000
50-day moving average ³	2.6471
200-day moving average ³	2.1290

Share statistics

Avg vol (3-month) ³	2.84M
Avg vol (10-day) ³	1.4M
Shares outstanding ⁵	187.02M
Implied shares outstanding ⁶	187.02M
Float ⁸	100.11M
% held by insiders ¹	18.47%
% held by institutions ¹	70.66%
Shares short (15 Apr 2024) ⁴	16.07M
Short ratio (15 Apr 2024) ⁴	4.17
Short % of float (15 Apr 2024) ⁴	11.70%
Short % of shares outstanding (15 Apr 2024) ⁴	8.59%
Shares short (prior month 15 Mar 2024) ⁴	15.81M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	-438.32%

Management effectiveness

Return on assets (ttm)	-29.84%
Return on equity (ttm)	-294.04%

Income statement

Revenue (ttm)	15.45M
Revenue per share (ttm)	0.13
Quarterly revenue growth (yoy)	44.00%
Gross profit (ttm)	N/A
EBITDA	-70M
Net income avi to common (ttm)	-111.57M
Diluted EPS (ttm)	-0.9600
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	143.94M
Total cash per share (mrq)	0.77
Total debt (mrq)	61.88M
Total debt/equity (mrq)	82.58%
Current ratio (mrq)	4.08
Book value per share (mrq)	0.40

Cash flow statement

Operating cash flow (ttm)	-73.02M
Levered free cash flow (ttm)	-68.51M